MedTrace Logo

Neurophysiologic Biomarkers for Cognitive Rehabilitation

NCT05945602 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-10-09

No results posted yet for this study

Summary

Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.

Conditions

  • Schizophrenia Spectrum Disorders

Interventions

OTHER

Neurophysiologic Biomarker Assessments

Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Juan Molina, MD · VA San Diego Healthcare System, San Diego, CA

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05945602 on ClinicalTrials.gov